Abstract
Objective: To review recent epidemiologic studies of vaccination and melanoma risk as well as critically discuss the different melanoma vaccines under investigation in multicenter phase III melanoma vaccine trials. Data Sources: A retrospective review of the literature. Study Selection: Studies included those on the risk of melanoma and vaccination, historically relevant data, and ongoing or recently published phase III melanoma vaccine trials. The referenced study designs and methodologies varied. Data extraction and Synthesis: 3 reviewers extracted Data and the main results are presented in a quantitative descriptive manner. Conclusion: Vaccine therapy of melanoma remains promising, given the associated low toxicity. Epidemiologic studies suggest a role for vaccines against certain infectious diseases in melanoma prevention. While results of ongoing phase III melanoma vaccines trials may open new avenues for disease prevention, a better understanding of immune responses to melanoma vaccines will be necessary.
Keywords: immunosuppression, bacille calmette-guerin (bcg), fibrosarcoma, t-lymphocytes, melanoma vaccines, immune system, adjuvant chemotherapy, delayed-type hypersensitivity (dth), viral oncolysates
Current Cancer Therapy Reviews
Title: Vaccine Therapy of Melanoma: An Update
Volume: 1 Issue: 2
Author(s): Marie-France Demierre, Susan M. Swetter and Vernon K. Sondak
Affiliation:
Keywords: immunosuppression, bacille calmette-guerin (bcg), fibrosarcoma, t-lymphocytes, melanoma vaccines, immune system, adjuvant chemotherapy, delayed-type hypersensitivity (dth), viral oncolysates
Abstract: Objective: To review recent epidemiologic studies of vaccination and melanoma risk as well as critically discuss the different melanoma vaccines under investigation in multicenter phase III melanoma vaccine trials. Data Sources: A retrospective review of the literature. Study Selection: Studies included those on the risk of melanoma and vaccination, historically relevant data, and ongoing or recently published phase III melanoma vaccine trials. The referenced study designs and methodologies varied. Data extraction and Synthesis: 3 reviewers extracted Data and the main results are presented in a quantitative descriptive manner. Conclusion: Vaccine therapy of melanoma remains promising, given the associated low toxicity. Epidemiologic studies suggest a role for vaccines against certain infectious diseases in melanoma prevention. While results of ongoing phase III melanoma vaccines trials may open new avenues for disease prevention, a better understanding of immune responses to melanoma vaccines will be necessary.
Export Options
About this article
Cite this article as:
Demierre Marie-France, Swetter M. Susan and Sondak K. Vernon, Vaccine Therapy of Melanoma: An Update, Current Cancer Therapy Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573394054021718
DOI https://dx.doi.org/10.2174/1573394054021718 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Women’s Health in Central America: The Complexity of Issues and the Need to Focus on Indigenous Healthcare
Current Women`s Health Reviews Gene Regulation in Cancer Gene Therapy Strategies
Current Medicinal Chemistry Emerging Immunotargets and Immunotherapies in Prostate Cancer
Current Drug Targets Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Proteochemometrics for the Prediction of Binding to the MHC Proteins
Letters in Drug Design & Discovery Recombinant Adeno-associated Virus 9-mediated Expression of Kallistatin Suppresses Lung Tumor Growth in Mice
Current Gene Therapy Assessment of Gene Transfer Using Imaging Methodology
Current Genomics Learning from Nature: Bioinspired Strategies Towards Antimicrobial Nanostructured Systems
Current Topics in Medicinal Chemistry Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy
Current Topics in Medicinal Chemistry A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Application of DODMA and Derivatives in Cationic Nanocarriers for Gene Delivery
Current Organic Chemistry The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Natural Products Mediated Regulation of Oxidative Stress and DNA Damage in Ultraviolet Exposed Skin Cells
Current Pharmaceutical Biotechnology Equol is Neuroprotective During Focal Cerebral Ischemia and Reperfusion that Involves p-Src and gp91<sup>phox</sup>
Current Neurovascular Research The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors
Current Topics in Medicinal Chemistry Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets